Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12054668 | 0.82 | KEAP1 (0.75) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL6696494 | 0.81 | KEAP1 (0.56) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL15904063 | 0.79 | KEAP1 (0.54) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL4959361 | 0.79 | CA1 (0.66) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL10193562 | 0.78 | KEAP1 (0.52) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL3648353 | 0.77 | KEAP1 (0.52) | KEAP1SMN1; SMN2ALDH1A1HTTCA12 | |
| SCHEMBL3099756 | 0.76 | HPGD (0.53) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL31041151 | 0.75 | KIF11 (0.79) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL4146317 | 0.75 | HPGD (0.63) | KEAP1SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL27787716 | 0.74 | CYP2C9 (0.51) | ALDH1A1LMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | claimed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | claimed |
| US-9216952-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2015-12-22 | — | — | US | claimed |
| EP-2411372-B1 | PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| EP-2411372-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | claimed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | claimed |
| WO-2010111348-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | claimed |
| CN-105622638-B | Pyrimidine or pyridopyridine ketone compounds and its preparation method and application | 广州必贝特医药技术有限公司 | 2018-10-02 | — | — | CN | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7071358-B2 | Arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1476423-A4 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1476423-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | Tularik Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | KEAP1 978/4885SMN1; SMN2 3493/4885ALDH1A1 1892/4885 |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | KEAP1 1148/4885SMN1; SMN2 2158/4885ALDH1A1 162/4885 |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | KEAP1 978/4885SMN1; SMN2 3493/4885ALDH1A1 1892/4885 |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | KEAP1 1148/4885SMN1; SMN2 2158/4885ALDH1A1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.